RxDoctor Payments DataLook up a doctor →

Arthur Romero, MD

Pulmonary Disease · Las Vegas, NVNPI 1669631743

Payments from drug & device makers

$326,775in general payments, 2019–2025

Across 453 payments — averaging $721.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$297K
  • Gilead$16K
  • AstraZeneca$5K
  • Pulmonx Corporation$3K
  • Boston Scientific$1K
  • Pinnacle Biologics, Inc$1K
  • plus $4K from 19 others

What the payments were for

  • Consulting fees$3,4881%
  • Speaking & faculty fees$2,2501%
  • Travel & lodging$54,79918%
  • Food & beverage$22,5347%
  • Education$227,32373%
  • Gifts$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$326,775 in reported general payments places this provider in the 95th percentile of 84 pulmonary disease providers in Nevada.

See all pulmonary disease providers in Nevada

Medicare billing

Part B allowed, 2024
$51,519
Medicare patients
131
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,180
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$13,630
Albuterol Sulfate HfaAlbuterol Sulfate14$438
Prednisone34$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$14$21,18021 claims
AstraZenecaBreztri Aerosphere$4,553$13,63014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 pulmonary disease providers in Nevada.

Other pulmonary disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →